Biostage, Inc. announced that it initiated start-up activities for its first clinical trial. The Phase 1, first-in-human study approved by the FDA will evaluate both safety and efficacy in up to ten patients requiring the removal of up to 6 cm of their esophagus (including cancer, trauma or birth defects) at up to five hospitals in the U.S. The primary endpoint is the development of a continuous biological neo-conduit at three months following implantation.
Harvard Apparatus Regenerative Technology Inc.
Equities
HRGN
US09074M2026
Advanced Medical Equipment & Technology
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.921 USD | -0.31% |
|
+11.49% | -41.46% |
1st Jan change | Capi. | |
---|---|---|
-41.46% | 41.81M | |
+4.18% | 211B | |
+8.00% | 185B | |
+31.86% | 158B | |
+33.21% | 113B | |
+2.28% | 64.32B | |
+21.14% | 55.66B | |
+0.11% | 48.41B | |
-6.76% | 37.82B | |
+0.78% | 35.57B |
- Stock Market
- Equities
- HRGN Stock
- News Harvard Apparatus Regenerative Technology Inc.
- Biostage, Inc. Initiates Study Start-Up Activities for Clinical Trial in Severe Esophageal Disease